doi: 10.3389/fnmol.2023.1305208 44 WeiMWuTChenN
In a phase 3 clinical trial, tirzepatide reduced 14.9% of body weight with a 5 mg dose, 19.5% with a 10 mg dose, and 20.9% with a 15 mg dose of tirzepatide
Arena R, Pronk NP, Lavie CJ
These medications, while regulating appetite and food reward pathways, can also lead to mood disturbances and altered eating behaviors, potentially affecting patient adherence
Aide soulager les douleurs musculaires et favorise la rcupration pendant lexercice physique
Considering the matched groups of our study, we can suggest that 2 weeks of adjuvant mitochondrial nutrients supplementation consisting of ALCAR, ALA, and CoQ10 has contributed to less development of anti-TB DILI